A population-based study of neuromyelitis optica in Caucasians

Neurology

Volumn 76, Issue 18, 2011, Pages 1589-1595

  Asgari, N ^a,e   Lillevang, S T ^b   Skejoe, H P B ^d   Falah, M ^b   Stenager, E ^a,e   Kyvik, K O ^c,e  

^a Multiple Sclerosis Clinic of Southern Jutland   (Denmark)

^b Department of Clinical Immunology ^*  (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d THAVA Imaging Diagnostic Centre   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BETA INTERFERON; NATALIZUMAB; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN DISEASE; BRAINSTEM SYNDROME; CAUCASIAN; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DENMARK; ETHNIC GROUP; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; HUMAN; INCIDENCE; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOLOGY; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; DENMARK; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PREVALENCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 79955581259     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182190f74     Document Type: Article

References (25)

1. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461. (Pubitemid 34755161)
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815. (Pubitemid 47238676)
3. Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: changing concepts. J Neuroimmunol 2007;187:126-138. (Pubitemid 47007701)
4. Asgari N, Owens T, Frokiaer J, Stenager E, Lillevang ST, Kyvik KO. Neuromyelitis optica (NMO): an autoimmune disease of the central nervous system (CNS). Acta Neurol Scand Epub 2010 Sep 29.
5. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114. (Pubitemid 29442132)
6. Wu JS, Zhang MN, Carroll WM, Kermode AG. Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatry 2008; 79:1022-1026.
7. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001;56:507-514. (Pubitemid 32172877)
8. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59: 566-569. (Pubitemid 43358081)
9. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019-1032.
10. de Seze J, Stojkovic T, Ferriby D, et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002;197:57-61. (Pubitemid 34462145)
11. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489. (Pubitemid 43958540)
12. Fazio R, Malosio ML, Lampasona V, et al. Anti-aquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler 2009;15:1153-1163.
13. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477. (Pubitemid 41186945)
14. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008;15:99-105.
15. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72:712-717.
16. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-1482. (Pubitemid 41552787)
17. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-1174.
18. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120: 2059-2069. (Pubitemid 27493740)
19. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
20. Sellner J, Luthi N, Buhler R, et al. Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol 2008;15:398-405. (Pubitemid 351422397)
21. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009;256:1891-1898.
22. Collongues N, Marignier R, Zephir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010;74:736-742.
23. Nickelsen TN. [Data validity and coverage in the Danish National Health Registry: a literature review.] Ugeskr Laeger 2001;164:33-37. (Pubitemid 34065463)
24. Krampla W, Aboul-Enein F, Jecel J, et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 2009;19: 2535-2543.
25. Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol 2008;318:343-356.